# A Multiple Ascending Dose Trial of CVL-231 in Subjects With Schizophrenia

> **NCT04136873** · PHASE1 · COMPLETED · sponsor: **Cerevel Therapeutics, LLC** · enrollment: 130 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** CVL-231
- **DRUG:** Matching Placebo

## Key facts

- **NCT ID:** NCT04136873
- **Lead sponsor:** Cerevel Therapeutics, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-15
- **Primary completion:** 2021-05-07
- **Final completion:** 2021-06-03
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2021-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04136873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04136873, "A Multiple Ascending Dose Trial of CVL-231 in Subjects With Schizophrenia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04136873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*